Migration Characteristics and Mechanism of Active Components From Jieyu Anshen Granule in Different Insomnia Mouse Models.

Authors

Shiqi Yan, Mengting Lu, Ping Sun, Run Wan, Yong Ge, Jia Yan, Yuhang Zhang, Mo Sun, Xiang Xu, Yaoqun Wu, Chenning Zhang

Published in

Rapid communications in mass spectrometry : RCM. Volume 40. Issue 24. Pages e70195. Dec 30, 2026.

Abstract

Insomnia is a highly prevalent disorder with substantial health and socioeconomic impacts, for which traditional Chinese medicine is an important treatment option. Jieyu Anshen Granule (JYAS-G) shows excellent clinical efficacy in insomnia treatment, but its active components, in vivo migration characteristics and underlying mechanisms remain unclear.
Two mouse insomnia models induced by p-chlorophenylalanine (PCPA, chemical method) and sleep deprivation machine (SDM, physical method) were established respectively, and mice were administered with low and high doses of JYAS-G, with open field test used to evaluate the pharmacodynamic effects. UHPLC-Q-Orbitrap-MS combined with GNPS was applied to systematically identify the in vitro components of JYAS-G and its migration profiles in mouse plasma, liver, heart, prefrontal cortex, hippocampus, and hypothalamus.
The SDM model induced insomnia with manic-like behaviors, which were significantly ameliorated by JYAS-G, whereas the PCPA model produced no significant insomnia-like phenotypes under the current conditions. In total, 89 in vitro components and 43 blood-absorbed components of JYAS-G were identified, showing marked tissue-specific distribution. Network pharmacology and molecular docking identified core components, including furanogermenone and curcumenol, predicted to exert anti-insomnia effects by targeting ADORA2A, GABRB3, and SLC6A4 and regulating the neuroactive ligand-receptor interaction pathway.
This study characterizes the in vivo migration characteristics of JYAS-G and provides insights into its multi-target anti-insomnia mechanism, while comparing the modeling differences between two common insomnia animal models. These findings provide scientific evidence for the rational clinical application and further development of JYAS-G.

PMID:
42865225
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.